Analysts expect Editas Medicine, Inc. (NASDAQ: EDIT) to post ($ 0.78) earnings per share for the current quarter, Zacks Investment Research reports. Five analysts have released estimates for Editas Medicine’s revenue, with estimates ranging from ($ 0.91) to ($ 0.65). Editas Medicine posted earnings per share of ($ 1.00) in the same quarter last year, suggesting a positive year-over-year growth rate of 22%. The company is expected to release its next results on Thursday, February 24.

On average, analysts predict that Editas Medicine will report annual earnings of ($ 3.08) per share for the current fiscal year, with EPS estimates ranging from ($ 3.59) to ($ 2.84) . For the next year, analysts predict the company will post earnings of ($ 3.40) per share, with EPS estimates ranging from ($ 3.70) to ($ 3.12). Zacks’ EPS calculations are an average based on a survey of seller-side research analysts who cover Editas Medicine.

Editas Medicine (NASDAQ: EDIT) last reported its quarterly results on Monday, November 8. The company reported ($ 0.57) earnings per share (EPS) for the quarter, beating analyst consensus estimates ($ 0.81) by $ 0.24. The company posted revenue of $ 6.20 million for the quarter, compared to a consensus estimate of $ 4.92 million. Editas Medicine recorded a negative return on equity of 38.28% and a negative net margin of 871.91%. The company’s quarterly revenue was down 90.1% year-on-year. During the same period of the previous year, the company posted earnings per share of $ 0.12.

A number of research analysts have recently published reports on EDIT stocks. Oppenheimer downgraded Editas Medicine from a “market performance” rating to an “outperformance” rating and raised its price target for the company from $ 42.00 to $ 80.00 in a report released on Thursday 9 September. Robert W. Baird reaffirmed a “buy” note on the shares of Editas Medicine in a report released on Wednesday, October 20. Chardan Capital reissued a “buy” note and issued a price target of $ 75 on shares of Editas Medicine in a report released on Thursday, September 30. SVB Leerink resumed coverage of Editas Medicine in a report published on Tuesday, October 19. They issued a “market performance” rating and a target price of $ 41.00 for the stock. Finally, Stifel Nicolaus lowered his price target on Editas Medicine from $ 65.00 to $ 46.00 and set a “hold” rating on the stock in a report released on Thursday, September 30. Three analysts gave the stock a sell rating, five assigned a conservation rating, and nine gave the stock a buy rating. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $ 57.27.

NASDAQ: EDIT shares traded up $ 0.18 at noon on Thursday, reaching $ 29.72. 37,632 shares of the company were traded for an average volume of 1,569,131. The company has a market capitalization of $ 2.03 billion, a price / earnings ratio of -9.16 and a beta of 2.00. Editas Medicine has a one-year minimum of $ 26.82 and a one-year maximum of $ 99.95. The stock has a 50-day moving average of $ 34.58 and a 200-day moving average of $ 44.69.

In related news, Executive Vice President Lisa Anne Michaels sold 1,568 shares in a trade dated Friday, November 12. The stock was sold for an average price of $ 38.33, for a total trade of $ 60,101.44. The transaction was disclosed in a legal file with the Securities & Exchange Commission, accessible through this link. Additionally, CEO James C. Mullen sold 13,805 shares in a trade dated Monday, October 18. The stock was sold for an average price of $ 38.03, for a total value of $ 525.04.15. Disclosure of this sale can be found here. Insiders sold 15,660 shares of the company valued at $ 596,761 during the last quarter. 0.94% of the shares are currently held by company insiders.

Hedge funds and other institutional investors have recently increased or reduced their stakes in the company. Royal Bank of Canada increased its holdings in Editas Medicine by 24.0% in the second quarter. Royal Bank of Canada now owns 62,525 shares of the company valued at $ 3,541,000 after purchasing an additional 12,087 shares in the last quarter. Man Group plc increased its stake in Editas Medicine by 88.8% during the 2nd quarter. Man Group plc now owns 14,041 shares of the company valued at $ 796,000 after purchasing an additional 6,603 shares in the last quarter. The State Board of Administration of Florida Retirement System increased its stake in the shares of Editas Medicine by 21.9% in the 2nd quarter. The Florida State Pension System Board now owns 29,796 shares of the company valued at $ 1,688,000 after purchasing an additional 5,361 shares in the last quarter. HITE Hedge Asset Management LLC purchased a new stake in the shares of Editas Medicine in the second quarter for a value of approximately $ 1,192,000. Finally, Bank of New York Mellon Corp increased its stake in the shares of Editas Medicine by 7.6% in the second quarter. Bank of New York Mellon Corp now owns 273,254 shares of the company valued at $ 15,477,000 after purchasing an additional 19,212 shares in the last quarter. Institutional investors and hedge funds hold 74.58% of the company’s shares.

Company profile Editas Medicine

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered and regularly spaced short palindromic repeats (CRISPR) and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J.

Further Reading: What Are the Benefits of a Growth and Income Fund?

Get a Free Copy of Zacks’ Research Report on Editas Medicine (EDIT)

For more information on Zacks Investment Research’s research offerings, visit Zacks.com

This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team before publication. Please send any questions or comments about this story to [email protected]

Should you invest $ 1,000 in Editas Medicine right now?

Before you consider Editas Medicine, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts quietly whisper to their clients to buy now before the broader market takes hold … and Editas Medicine was not on the list.

While Editas Medicine currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here